- MediciNova ( NASDAQ: MNOV ) said it started a first-in-human study of a new parenteral formulation of MN-166 (ibudilast).
- The company said the newly developed MN-166 (ibudilast) formulation will provide an additional option besides the current oral formulation.
- "With MN-166 expected to be effective to treat a variety of diseases, we believe expanding to a parenteral formulation increases the feasibility of treating more target indications, thus increasing the value of MN-166," said MediciNova Chief Medical Officer Kazuko Matsuda.
- In April, the company reported data from a phase 2 trial of MN-166 for alcohol use disorder, showing that the drug reduced alcohol craving on non-drinking days.
For further details see:
MediciNova begins study of parenteral formulation of MN-166